RESUMO: "Benefícios terapêuticos da Sideroxylon obtusifolium (Humb. ex Roem. & Schult.) T.D. Penn., Sapotaceae, em modelos experimentais de dor e inflamação". A Sideroxylon obtusifolium (Humb. ex Roem. & Schult.) T.D. Penn., Sapotaceae, é utilizada na medicina popular em processos dolorosos e inflamatórios. Para avaliar as atividades analgésica e anti-inflamatória desta planta, estudos foram realizados com o extrato etanólico (EE) da entrecasca (100-400 mg/kg). O tratamento oral único dos animais com o EE inibiu (200 e 400 mg/kg, p<0,01) o efeito do ácido acético e reduziu (100, 200 e 400 mg/kg, p<0,001) o efeito da formalina na segunda fase; entretanto, não apresentou efeito no teste da placa quente. A formação de edema e a migração de leucócitos para a cavidade peritoneal induzidas pela carragenina foram reduzidas pelo tratamento com o EE (100, 200 e 400 mg/kg, p<0,001). Desta forma conclui-se que o EE da Sideroxylon obtusifolium apresenta atividades antinociceptiva e anti-inflamatória, suportando seu uso popular no tratamento da dor e de doenças inflamatórias.Unitermos: anti-inflamatória, antinociceptiva, Sideroxylon obtusifolium, Sapotaceae. ABSTRACT:Sideroxylon obtusifolium (Humb. ex Roem. & Schult.) T.D. Penn., Sapotaceae, is a plant with analgesic and anti-inflammatory activities used in folk medicine. In order to evaluate the actions of this plant, studies were performed on antinociceptive and antiinflammatory activities with the ethanol extract (EE) of inner bark (100-400 mg/kg). Oral treatment with the EE elicited inhibitory activity (200 and 400 mg/kg, p<0.01) on acetic acid effect and reduced (100, 200, and 400 mg/kg, p<0.001) the formalin effect at the secondphase, however it did not elicit any inhibitory effect on hot-plate test. Carrageenan-induced oedema formation and leukocyte migration into the peritoneal cavity were reduced with the EE at 100, 200, and 400 mg/kg (p<0.001). In conclusion, the EE of Sideroxylon obtusifolium shows antinociceptive and anti-inflammatory activities, supporting the folkloric usage of the plant to treat pain and various inflammatory diseases.

SUMMARYIntroduction:According to the guidelines, the viral load of 2,000 IU/mL is considered the level to differentiate between inactive carriers and HBeAg(-) chronic hepatitis B patients. Even so, liver damage may be present in patients with lower viral load levels, mainly related to regional variations. This study aims to verify the presence of liver injury in patients with viral load below 2,000 IU/mL.Methods:Patients presenting HBsAg(+) for more than six months, Anti-HBe(+)/HBeAg(-), viral load below 2,000 IU/mL and serum ALT levels less than twice the upper limit of normality underwent liver biopsy. Clinical and laboratory characteristics were evaluated in relation to the degree of histologic alteration. Liver injury was considered advanced when F ≥ 2 and/or A ≥ 2 by the METAVIR classification.Results:11/27 (40.7%) patients had advanced liver injury, with a mean viral load of 701.0 (± 653.7) IU/mL versus 482.8 (± 580.0) IU/mL in patients with mild injury. The comparison between the mean values of the two groups did not find a statistical difference (p = 0.37). The average of serum aminotransferases was not able to differentiate light liver injury from advanced injury.Conclusions:In this study, one evaluation of viral load did not exclude the presence of advanced liver damage. Pathologic assessment is an important tool to diagnose advanced liver damage and should be performed in patients with a low viral load to indicate early antiviral treatment.

No abstract